Caption Management LLC Has $692,000 Stock Holdings in Bicycle Therapeutics PLC Sponsored ADR $BCYC

Key Points

• Caption Management LLC reduced its stake in Bicycle Therapeutics PLC by 50% in the first quarter, retaining 81,559 shares valued at $692,000.
• Bicycle Therapeutics reported a loss of $1.14 EPS in its most recent quarterly earnings, missing analysts' expectations by $0.19 and generating revenue of only $2.90 million.
• Analysts have set a consensus target price of $22.22 for Bicycle Therapeutics, with ratings ranging from "Buy" to "Hold" from various financial institutions.

Caption Management LLC reduced its holdings in shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Free Report) by 50.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 81,559 shares of the company's stock after selling 81,517 shares during the quarter. Caption Management LLC owned approximately 0.12% of Bicycle Therapeutics worth $692,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in BCYC. Barclays PLC boosted its stake in shares of Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock worth $37,000 after acquiring an additional 2,345 shares during the period. Jane Street Group LLC boosted its stake in shares of Bicycle Therapeutics by 18.9% during the 4th quarter. Jane Street Group LLC now owns 23,991 shares of the company's stock worth $336,000 after acquiring an additional 3,811 shares during the period. Bank of America Corp DE boosted its stake in shares of Bicycle Therapeutics by 2.1% during the 4th quarter. Bank of America Corp DE now owns 392,859 shares of the company's stock worth $5,500,000 after acquiring an additional 7,994 shares during the period. Baker BROS. Advisors LP boosted its stake in shares of Bicycle Therapeutics by 15.8% during the 4th quarter. Baker BROS. Advisors LP now owns 10,885,357 shares of the company's stock worth $152,395,000 after acquiring an additional 1,485,397 shares during the period. Finally, Fcpm Iii Services B.V. boosted its stake in shares of Bicycle Therapeutics by 47.5% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company's stock worth $48,333,000 after acquiring an additional 1,112,369 shares during the period. 86.15% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BCYC. Royal Bank Of Canada set a $27.00 target price on Bicycle Therapeutics and gave the stock an "outperform" rating in a research note on Monday, August 11th. Oppenheimer restated an "outperform" rating and issued a $44.00 price target (down from $48.00) on shares of Bicycle Therapeutics in a research note on Monday, August 11th. Morgan Stanley reduced their price target on Bicycle Therapeutics from $17.00 to $13.00 and set an "equal weight" rating for the company in a research note on Tuesday, August 12th. Finally, JMP Securities reduced their price target on Bicycle Therapeutics from $22.00 to $10.00 and set a "market outperform" rating for the company in a research note on Tuesday, August 12th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Bicycle Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $22.22.

Bicycle Therapeutics Price Performance

BCYC traded down $0.10 during trading on Wednesday, hitting $7.10. The stock had a trading volume of 180,495 shares, compared to its average volume of 251,371. The company has a 50 day moving average price of $7.66 and a 200-day moving average price of $8.35. The firm has a market cap of $491.68 million, a price-to-earnings ratio of -2.02 and a beta of 1.41. Bicycle Therapeutics PLC Sponsored ADR has a one year low of $6.10 and a one year high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its quarterly earnings data on Friday, August 8th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.19). The company had revenue of $2.90 million during the quarter, compared to analyst estimates of $9.43 million. Bicycle Therapeutics had a negative net margin of 1,257.00% and a negative return on equity of 32.43%. As a group, sell-side analysts predict that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.